Aha! The third poster. Thanks for finding this!
This is an outstanding result:
"potent cytolytic activity against triple negative breast cancer and HCC tumor cells. OnCARlytics demonstrated expression of CD19t and robust in vivo anti-tumor efficacy against human HCC tumor xenografts. In summary, CD19 ARTEMIS® T-Cells combined with onCARlytics is a potentially effective immunotherapy strategy for the treatment of patients with HCC and can be applied to other solid tumors."
A potent effect in triple negative breast cancer AND in liver cancer. The Artemis/OnCARlytics combination cert mainly looks like a winner.
Confirmation here that they are highly interested, because they end with: "CD19 ARTEMIS® T-Cells and onCARlytics combination therapy efficacy will be tested in multiple in vivo models."
That sounds like Ph 1 clinical trials to me, against more than one solid tumour type.
Cheers
Dave :
Media Thread, page-7454
-
- There are more pages in this discussion • 7,215 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
